4,4,4-三氟-1-(2-菲基)-1,3-丁烷二酮 | 15389-33-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 中文名称: 4,4,4-三氟-1-(2-菲基)-1,3-丁烷二酮
• 英文名称: 4,4,4-Trifluoro-1-phenanthren-2-yl-butane-1,3-dione
• 英文别名: 4,4,4-Trifluoro-1-(phenanthren-2-yl)butane-1,3-dione；4,4,4-trifluoro-1-phenanthren-2-ylbutane-1,3-dione
• CAS: 15389-33-0
• 化学式: C₁₈H₁₁F₃O₂
• 分子量: 316.279
• InChiKey: AQNQWKSQLGAUBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  4,4,4-三氟-1-(2-菲基)-1,3-丁烷二酮 在 盐酸 、 platinum(IV) oxide 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 、 乙酸乙酯 为溶剂， 生成 2-氨基-N-[4-[5-(2-菲基)-3-(三氟甲基)-1H-吡唑-1-基]苯基]乙酰胺
  参考文献：
  名称：

  Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

  摘要：

  Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.018
• 作为产物：
  描述：

  三氟乙酸乙酯 、 2-乙酰基菲 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 以95%的产率得到4,4,4-三氟-1-(2-菲基)-1,3-丁烷二酮
  参考文献：
  名称：

  Compounds and methods for inducing apoptosis in proliferating cells

  摘要：

  用于诱导增殖细胞凋亡的化合物，特别是癌细胞，包括但不限于前列腺癌、白血病、非小细胞肺癌、结肠癌、中枢神经系统癌、黑色素瘤、卵巢癌、肾癌、膀胱癌、淋巴瘤和乳腺癌。这些化合物在治疗雄激素非依赖性癌症特别有效，包括激素难治性前列腺癌。还提供了使用本发明化合物治疗患有癌症的受试者的方法。此外，还提供了使用本发明化合物治疗、抑制或延迟受试者癌症发生的方法。此外，还提供了使用本发明化合物诱导快速增殖细胞凋亡的方法，特别是虽然不一定是癌细胞。

  公开号：

  US20030236294A1

文献信息

• MODIFICATION OF LAYERED SILICATES FOR LUMINESCENCE ACTIVATION
  申请人：Klauth Peter

  公开号：US20120107624A1

  公开（公告）日：2012-05-03

  The invention relates to a method for producing a luminescent layered silicate composite. The method according to the invention is characterized in that at least one luminescent dye, in particular fluorescent dye, on the basis of at least one complex, essentially a chelate complex, of at least one element of the rare earth elements (“rare earth complex”) is introduced between and/or stored in at least two layers of at least one layered silicate (“layered silicate layers”) respectively or that at least one luminescent dye, in particular fluorescent dye, on the basis of at least one complex, essentially a chelate complex, of at least one element of the rare earth elements (“rare earth complex”) is combined with a layered silicate to form a composite. The luminescent layered silicate composite according to the invention can be used for marking objects, for example plastic-based objects, or in the field of bioanalysis.
• [EN] ELECTROLUMINESCENT MATERIALS AND DEVICES<br/>[FR] MATIERES ELECTROLUMINESCENTES ET DISPOSITIFS LES CONTENANT
  申请人：ELAM T LTD

  公开号：WO2004013252A1

  公开（公告）日：2004-02-12

  An electroluminescent device in which the electroluminescent layer comprises a rare earth, lanthanide or actinide bis[tris(pyrazolyl)borate)mono(acetonate).
• Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus
  作者：Hao-Chieh Chiu、Su-Lin Lee、Naval Kapuriya、Dasheng Wang、Yi-Ru Chen、Sung-Liang Yu、Samuel K. Kulp、Lee-Jene Teng、Ching-Shih Chen

  DOI：10.1016/j.bmc.2012.06.018

  日期：2012.8

  Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA. (C) 2012 Elsevier Ltd. All rights reserved.
• Compounds and methods for inducing apoptosis in proliferating cells
  申请人：——

  公开号：US20030236294A1

  公开（公告）日：2003-12-25

  Compounds useful for inducing apoptosis in proliferative cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-smalll cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, bladder cancer, lymphoma, and breast cancer. These compounds are particularly useful in the treatment of androgen-independent cancers, including hormone-refractory prostate cancer. Further provided are methods of treating cancer in a subject in need of such treatment using the compounds of the present invention. Further provided are methods for using the compounds of the present invention to treat, inhibit, or delay the onset of cancer in a subject. Further provided are methods of inducing apoptosis in rapidly proliferating cells, particularly, though not necessarily cancer cells, using the compounds of the present invention.

  用于诱导增殖细胞凋亡的化合物，特别是癌细胞，包括但不限于前列腺癌、白血病、非小细胞肺癌、结肠癌、中枢神经系统癌、黑色素瘤、卵巢癌、肾癌、膀胱癌、淋巴瘤和乳腺癌。这些化合物在治疗雄激素非依赖性癌症特别有效，包括激素难治性前列腺癌。还提供了使用本发明化合物治疗患有癌症的受试者的方法。此外，还提供了使用本发明化合物治疗、抑制或延迟受试者癌症发生的方法。此外，还提供了使用本发明化合物诱导快速增殖细胞凋亡的方法，特别是虽然不一定是癌细胞。

表征谱图